Viralgen Commercial

Commercial-scale Gene Therapy Manufacturing


Viralgen Commercial represents the next phase of an ambitious project launched in 2017. Once completed, it will be the largest manufacturing facility in the world for adeno-associated virus (AAV) vectors intended for use in the treatment of diseases. Large-scale manufacturing will allow Viralgen to supply the product beyond clinical trials. In doing so, Viralgen Commercial democratizes access to gene therapy—both in terms of production volume and speed—by increasing yield and output while reducing manufacturing costs.

CEO
Javier García Cogorro

WEBSITE

https://viralgen.com

EXITED COMPANY
2019-2021 (Acquired by Bayer)

DETAILS
Viralgen Commercial
Parque Científico y Tecnológico de Gipuzkoa
Paseo Mikeletegi, 83.
20009 San Sebastián, Spain

Contact us

Columbus Venture Partners
Ronda Guglielmo Marconi, 8.
46980 – Parque Tecnológico (Valencia)

    Before giving your consent, please read the information on data protection
    +

    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.